05.03.2022

Affini-T Therapeutics’ KRAS TCR T Cell Therapy Program to be Presented at the Annual Meeting of the American Society of Gene and Cell Therapy

04.05.2022

Affini-T Expands Board of Directors with Appointments of Michael Varney, Ph.D., and Daniel Faga

03.22.2022

Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations

01.10.2022

Affini-T Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

Corporate Presentations

01.07.2022

Corporate Deck for Affini-T Therapeutics, Inc. at 40th Annual J.P. Morgan Healthcare Conference